

Special Issue

Personalized Medicine and Management of COVID-19

Message from the Guest Editors

COVID-19 poses a major global threat to humankind, inflicting devastating consequences as to public health. Understanding its pathological and epidemiological variation along with providing a personalized treatment will greatly reduce its damage and enhance the preparedness for a future pandemic caused by either COVID-19 or other infectious diseases. As the pandemic has so far lasted a year and half, studies with solid experimental and a considerable amount of data, particularly on molecular mechanisms and overall genetics, will provide valuable information for both the general public and the scientific community. We are looking for papers that provide a novel contribution to optimize the personalization of medicine covering all aspects of COVID-19. For example, we welcome papers related to personalized and sex difference in pathological classification, diagnosis, treatment, recovering process, and COVID-19-related sequelae along with the variations in disease epidemiological patterns, transmission and management according to countries, regions, sex and races.

Guest Editors

Prof. Dr. Weikuan Gu

Department of Orthopedic Surgery and BME-Campbell Clinic,
University of Tennessee Health Science Center, Memphis, TN 38163,
USA

Prof. Dr. Lotfi Aleya

National Centre for Scientific Research (CNRS 6249), Université de
Franche-Comté, F-25030 Besançon, France

Deadline for manuscript submissions

closed (25 April 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed




mdpi.com/si/90868

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).